Cheng-Ke Li

Title: **Innovative Contributions of Cheng-Ke Li in Anti-Angiogenesis Technologies**

Introduction

Cheng-Ke Li, an esteemed inventor based in Taoyuan, Taiwan, has made significant strides in the field of biotechnology with a focus on anti-angiogenesis. With a remarkable portfolio of three patents, his innovative work aims to address critical health issues linked to angiogenesis-associated diseases.

Latest Patents

One of Cheng-Ke Li's notable inventions is the "Anti-angiogenesis fusion protein and uses thereof." This development features a bi-functional fusion protein, designated as (AT)a-Fc-(VT)b, which simultaneously targets vascular endothelial growth factor (VEGF) and angiopoietins (ANGs). In this formula, AT represents the ANG binding motif, while VT signifies the VEGF binding motif. The fragment crystallizable region (Fc) is sourced from the N-terminal of Immunoglobulin G (IgG). The integers a and b range from 1 to 10, allowing for flexibility in the design of these fusion proteins. Remarkably, these proteins consist of two or more domains derived from human proteins, making them expectedly non-immunogenic and potentially viable as therapeutic agents for treating diseases linked to abnormal angiogenesis.

Career Highlights

Cheng-Ke Li is currently associated with Trican Biotechnology Co., Ltd., where he continues to push the boundaries of innovation in biotechnology. His work not only showcases his inventive prowess but also contributes to the advancement of medical treatments aimed at combating diseases that arise from problematic blood vessel formation.

Collaborations

Throughout his career, Cheng-Ke Li has collaborated with talented colleagues including Huang-Tsu Chen and Jiun-Shyang Leou. Together, they forge a dynamic research environment that fosters groundbreaking discoveries and optimizes the impact of their collective efforts on the biotechnology industry.

Conclusion

As Cheng-Ke Li continues to innovate and expand his intellectual contributions to biotechnological applications, his commitment to developing therapeutic solutions for angiogenesis-related conditions remains commendable. The persistent pursuit of excellence in his work is indicative of the potential transformations his inventions can bring to the medical field.